Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma
Thyroid dysfunction (TD) induced by programmed death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been widely reported. However, the effects of ICI-induced TD on the survival of patients with esophageal squamous cell carcinoma (ESCC) have not been descri...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2022/4015897 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306139265597440 |
|---|---|
| author | Ying Chen Lei Zhuang Danhong Zhang Xianghui Du Liming Sheng |
| author_facet | Ying Chen Lei Zhuang Danhong Zhang Xianghui Du Liming Sheng |
| author_sort | Ying Chen |
| collection | DOAJ |
| description | Thyroid dysfunction (TD) induced by programmed death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been widely reported. However, the effects of ICI-induced TD on the survival of patients with esophageal squamous cell carcinoma (ESCC) have not been described. Herein, a retrospective study was conducted, which 82 patients with advanced metastatic or recurrent ESCC treated with camrelizumab were enrolled. Twenty patients (24.4%) experienced TD during camrelizumab treatment with or without chemotherapy. The median onset time of TD was 1.7 months. The incidence of TD was 35.6% in patients who previously received thoracic radiotherapy versus 10.8% in patients who did not (P =0.009). Patients with TD had significantly longer median progression-free survival (5.5 months vs 3.5 months, P =0.035) and overall survival (26.7 months vs 11.5 months, P <0.001). TD is frequently observed in ESCC patients treated with camrelizumab and especially in patients who received radiotherapy previously. ESCC patients with TD during ICIs treatment often have better prognosis. |
| format | Article |
| id | doaj-art-39b1ee7a7f054d76b9bf5165b2d4863a |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-39b1ee7a7f054d76b9bf5165b2d4863a2025-08-20T03:55:11ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/4015897Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell CarcinomaYing Chen0Lei Zhuang1Danhong Zhang2Xianghui Du3Liming Sheng4Department of Thoracic RadiotherapyDepartment of Thoracic RadiotherapyDepartment of Thoracic RadiotherapyDepartment of Thoracic RadiotherapyDepartment of Thoracic RadiotherapyThyroid dysfunction (TD) induced by programmed death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been widely reported. However, the effects of ICI-induced TD on the survival of patients with esophageal squamous cell carcinoma (ESCC) have not been described. Herein, a retrospective study was conducted, which 82 patients with advanced metastatic or recurrent ESCC treated with camrelizumab were enrolled. Twenty patients (24.4%) experienced TD during camrelizumab treatment with or without chemotherapy. The median onset time of TD was 1.7 months. The incidence of TD was 35.6% in patients who previously received thoracic radiotherapy versus 10.8% in patients who did not (P =0.009). Patients with TD had significantly longer median progression-free survival (5.5 months vs 3.5 months, P =0.035) and overall survival (26.7 months vs 11.5 months, P <0.001). TD is frequently observed in ESCC patients treated with camrelizumab and especially in patients who received radiotherapy previously. ESCC patients with TD during ICIs treatment often have better prognosis.http://dx.doi.org/10.1155/2022/4015897 |
| spellingShingle | Ying Chen Lei Zhuang Danhong Zhang Xianghui Du Liming Sheng Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma Journal of Immunology Research |
| title | Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
| title_full | Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
| title_fullStr | Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
| title_full_unstemmed | Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
| title_short | Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma |
| title_sort | thyroid dysfunction as a predictive indicator in camrelizumab of advanced esophageal squamous cell carcinoma |
| url | http://dx.doi.org/10.1155/2022/4015897 |
| work_keys_str_mv | AT yingchen thyroiddysfunctionasapredictiveindicatorincamrelizumabofadvancedesophagealsquamouscellcarcinoma AT leizhuang thyroiddysfunctionasapredictiveindicatorincamrelizumabofadvancedesophagealsquamouscellcarcinoma AT danhongzhang thyroiddysfunctionasapredictiveindicatorincamrelizumabofadvancedesophagealsquamouscellcarcinoma AT xianghuidu thyroiddysfunctionasapredictiveindicatorincamrelizumabofadvancedesophagealsquamouscellcarcinoma AT limingsheng thyroiddysfunctionasapredictiveindicatorincamrelizumabofadvancedesophagealsquamouscellcarcinoma |